Investor's Business Daily on MSN

Rhythm grabs a new obesity approval; how it edged in where Lilly, Novo have fallen flat

Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic ...
Healio

FDA expands approval for setmelanotide to patients with hypothalamic obesity

The FDA has approved an expanded indication for setmelanotide to treat children and adults with acquired hypothalamic obesity ...
Fierce Pharma

Rhythm's Imcivree scores 'transformative' FDA approval in brain damage-related obesity

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod ...
BioSpace

Rhythm Bounces Back from Phase 3 Fail with FDA Nod for Rare Obesity Injection

At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.